



## \$762k R&D Tax Incentive Received

**Sydney:** AI and Medical Technology Company Echo IQ Limited (ASX: **EIQ**) (“**Echo IQ**” or “**the Company**”) is pleased to confirm the receipt of \$762,662.01 under the Australian Government’s Research and Development (“**R&D**”) Tax Incentive Scheme.

The claim covers the financial year ended 30 June 2025. The refund recognises the Company’s expenditure incurred in R&D associated with the Company’s artificial intelligence innovation and the development of decision-support solutions for the detection of structural heart disease.

The R&D Tax Incentive Scheme is an Australian Government program developed to assist companies undertaking eligible research and development activities through refundable and non-refundable tax offsets. Eligible companies with turnover under \$20 million may receive a refundable offset of up to 43.5% of eligible R&D expenditure.

- ENDS -

**Authorised for release by the Board of Directors of Echo IQ Limited.**

**Investor Enquiries:**

Andrew Grover, Executive Chair  
[Andrew.grover@echoiq.ai](mailto:Andrew.grover@echoiq.ai) / [investor@echoiq.ai](mailto:investor@echoiq.ai)

Henry Jordan, Six Degrees Investor Relations  
[Henry.jordan@sdir.com.au](mailto:Henry.jordan@sdir.com.au) / +61 (0) 431 271 538

**ABOUT ECHO IQ**

Echo IQ uses AI-driven technology and proprietary software to improve decision making in Cardiology. The company is based in Sydney, Australia.

<sup>TM</sup>Registered trademark or trademark of Echo IQ Ltd. or its affiliates. © 2025 Echo IQ Ltd. All rights reserved.

For personal use only